Currently, dual HER2 blockade with trastuzumab and pertuzumab is recommended by the National Comprehensive Cancer Network (NCCN) guidelines as an important neoadjuvant therapy component for patients with early or locally advanced HER2-positive breast cancer (9). Here, ERBB2 is linked to breast cancer.